---
schema_version: "secwatch.filing_event.v1"
accession: "0001827090-25-000026"
form_type: "8-K"
ticker: "CERT"
cik: "0001827090"
company_name: "Certara, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T18:37:35.411978+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Certara Q1 2025 revenue up 10% to $106M; net income positive vs year-ago loss

## Summary
- Revenue $106.0M (+10% YoY); software rev $46.4M (+18%), services $59.6M (+4%).
- Net income $4.7M vs net loss of $4.7M in Q1 2024; adjusted EBITDA $34.8M (+20%).
- Reiterated full-year 2025 financial guidance.
- CEO cites FDA roadmap for reducing animal testing as opportunity for biosimulation.
- CFO notes strong commercial execution despite biopharma headwinds.

## SEC filing metadata
- accession: 0001827090-25-000026
- form_type: 8-K
- ticker: CERT
- cik: 0001827090
- company_name: Certara, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827090/000182709025000026/0001827090-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827090/000182709025000026/certara-20250505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001827090-25-000026
- JSON: https://secwatch.observer/filing/0001827090-25-000026.json
- Plain text: https://secwatch.observer/filing/0001827090-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.